NO942350L - Peptide compound with therapeutic activity - Google Patents

Peptide compound with therapeutic activity

Info

Publication number
NO942350L
NO942350L NO942350A NO942350A NO942350L NO 942350 L NO942350 L NO 942350L NO 942350 A NO942350 A NO 942350A NO 942350 A NO942350 A NO 942350A NO 942350 L NO942350 L NO 942350L
Authority
NO
Norway
Prior art keywords
therapeutic activity
peptide compound
ahx
ile
phe
Prior art date
Application number
NO942350A
Other languages
Norwegian (no)
Other versions
NO942350D0 (en
Inventor
Myles Edward Pierson
James Donald Rosamond
Original Assignee
Fisons Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929220543A external-priority patent/GB9220543D0/en
Priority claimed from GB929220761A external-priority patent/GB9220761D0/en
Application filed by Fisons Corp filed Critical Fisons Corp
Publication of NO942350L publication Critical patent/NO942350L/en
Publication of NO942350D0 publication Critical patent/NO942350D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/595—Gastrins; Cholecystokinins [CCK]
    • C07K14/5955—Gastrins; Cholecystokinins [CCK] at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Forbindelser med formel I, hvor R1 er OH eller OS03H; M er Met, Ahx eller Ile; G er Gly eller Sår; X er Met, Ahx, Ile, Phe eller Lys(R2); J er Asp, Asp(OBn), DAsp, MeAsp eller MeDAsp og L er Phe eller MePhe; med forskjellige forutsetninger; og farmasøytiske aksept- able derivater derav; nyttige som terapeutiske midler, spesielt for inhibisjon av foring.Compounds of formula I wherein R 1 is OH or OSO 3 H; M is Met, Ahx or Ile; G is Gly or Wound; X is Met, Ahx, Ile, Phe or Lys (R2); J is Asp, Asp (OBn), DAsp, MeAsp or MeDAsp and L is Phe or MePhe; with different conditions; and pharmaceutically acceptable derivatives thereof; useful as therapeutic agents, especially for inhibition of lining.

NO942350A 1991-12-20 1994-06-20 Peptide compound with therapeutic activity NO942350L (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81098591A 1991-12-20 1991-12-20
GB929220543A GB9220543D0 (en) 1992-09-29 1992-09-29 Pharmacologically active compounds
GB929220761A GB9220761D0 (en) 1992-10-02 1992-10-02 Pharmaceutically active compounds
PCT/GB1992/002369 WO1993013126A1 (en) 1991-12-20 1992-12-21 Peptide compounds having therapeutic activity

Publications (2)

Publication Number Publication Date
NO942350L true NO942350L (en) 1994-06-20
NO942350D0 NO942350D0 (en) 1994-06-20

Family

ID=27266393

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942350A NO942350L (en) 1991-12-20 1994-06-20 Peptide compound with therapeutic activity

Country Status (11)

Country Link
EP (1) EP0619823A1 (en)
JP (1) JPH08500324A (en)
AU (1) AU672186B2 (en)
CA (1) CA2126236A1 (en)
FI (1) FI942898A0 (en)
HU (1) HU211564A9 (en)
IL (1) IL104161A0 (en)
MX (1) MX9207458A (en)
NO (1) NO942350L (en)
NZ (1) NZ246195A (en)
WO (1) WO1993013126A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754248R (en) * 1969-08-01 1971-02-01 Farmaceutici Italia ACTIVITY POLYPEPTIDES
NZ218607A (en) * 1985-12-19 1989-10-27 Pennwalt Corp Tri-to acta-peptides with sulphate ester groups: obesity treatment
IE873084L (en) * 1986-11-18 1988-05-18 Pfizer Hospital Prod Peptides with sulfate ester groups
DK0495013T3 (en) * 1989-11-27 1995-07-24 Astra Ab Hexapeptides with sulfate ester groups

Also Published As

Publication number Publication date
EP0619823A1 (en) 1994-10-19
FI942898A (en) 1994-06-17
FI942898A0 (en) 1994-06-17
JPH08500324A (en) 1996-01-16
CA2126236A1 (en) 1993-07-08
HU211564A9 (en) 1995-12-28
MX9207458A (en) 1993-11-01
IL104161A0 (en) 1993-05-13
NO942350D0 (en) 1994-06-20
NZ246195A (en) 1995-11-27
AU3167893A (en) 1993-07-28
WO1993013126A1 (en) 1993-07-08
AU672186B2 (en) 1996-09-26

Similar Documents

Publication Publication Date Title
DE69831868D1 (en) Antithrombosemittel
IL133623A0 (en) Antithrombotic agents
TW336939B (en) Lipopeptide derivatives, a process for their preparation and their use
ATE374749T1 (en) INDOLE DERIVATIVES AS ANTI-INFLAMMATORY ACTIVE INGREDIENTS
ES2132393T3 (en) GUANIDINE DERIVATIVES USEFUL IN THERAPEUTICS.
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
MY123908A (en) Meta-azacyclic amino benzoic acid compounds and derivatives thereof
ES2161238T3 (en) USE OF 2-PHENYL-3-AROILBENZOTIOPHENES FOR THE PREPARATION OF A MEDICINAL PRODUCT TO INHIBIT ANGIOGENESIS AND ANGIOGENIC DISEASES.
ES2154669T3 (en) USE OF 2-PHENYL-3-AROILBENZOTIOPHENES FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE INHIBITION OF THE DEGRADATION OF CARTILAGO.
HUP0202803A2 (en) Titanium derived compounds, preparation and use thereof
ES2111352T3 (en) USE OF DIESTER PHOSPHATE FOR THE TREATMENT OF RETINAL DISEASES.
NO944933L (en) Procedure for inhibiting disease states of the breast
ZA922910B (en) Heterocylic pharmaceutical compounds preparation and use
NO944923L (en) Inhibition of weight gain or induction of weight loss
DE69132578D1 (en) Cephem derivatives
LU90732I2 (en) Synercid
NO942350L (en) Peptide compound with therapeutic activity
MY111439A (en) Thymosin alpha 1 derivatives
ATE282608T1 (en) QUINOXALINDIONES
DE69422629T2 (en) INDOLDER DERIVATIVES AS 5-ALPHA-REDUCTASE-1 INHIBITORS
HUP0102370A2 (en) Mumbaistatin, a process for its production and its use as a pharmaceutical
NO933691L (en) Thiocarbamate sulfoxide composition for abstinence from ingestion of ethanol
AU2042895A (en) Benzene derivatives and pharmaceutical composition
SE9201188L (en) New use
DE69528984D1 (en) INHIBITION OF LEUKOTRIA BIOSYNTHESIS BY URINE DERIVATIVES